Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01096160
Recruitment Status : Completed
First Posted : March 30, 2010
Results First Posted : August 12, 2019
Last Update Posted : August 12, 2019
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This study evaluated adverse events (AEs), study discontinuation due to AEs, and pharmacodynamics of MK-8266 in male participants with mild to moderate hypertension.

Condition or disease Intervention/treatment Phase
Hypertension Drug: MK-8226 BID, 1 mg Drug: MK-8266 BID, 1.8 mg Drug: MK-8266 TID, 1.8 mg Drug: MK-8266 TID, 2.4 mg Drug: Placebo BID (Panel A) Drug: Placebo BID (Panel B) Drug: Placebo TID (Panel C) Drug: Placebo TID (Panel D) Drug: Placebo TID (Panel E) Phase 1

Detailed Description:
This study evaluated AEs, discontinuation due to AEs, and effects on hemodynamic parameters, including systolic blood pressure (SBP) and aortic augmentation index (AIx), following multiple oral doses of MK-8266. Five serial panels, each consisting of eight participants (40 participants in Panels A, B, C, D, and E), were randomized to receive either MK-8266 or matching placebo twice daily (BID) or three times daily (TID) for 10 consecutive days. Although the original plan was to evaluate MK-8266 treatment in Panels D and E using both BID and TID regimens, the study actually evaluated identical TID regimens in these panels.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8266
Actual Study Start Date : March 1, 2010
Actual Primary Completion Date : November 1, 2010
Actual Study Completion Date : November 1, 2010

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Panel A: MK-8266 BID, 1 mg/Placebo
MK-8266 1 mg (0.7 mg in the morning [AM] + 0.3 mg in the evening [PM]), or as matching placebo BID.
Drug: MK-8226 BID, 1 mg
MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
Other Name: MK-8266

Drug: Placebo BID (Panel A)
Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.

Experimental: Panel B: MK-8266 BID, 1.8 mg/Placebo
MK-8266 1.8 mg (1 mg in the AM + 0.8 mg in the PM), or as matching placebo BID.
Drug: MK-8266 BID, 1.8 mg
MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
Other Name: MK-8266

Drug: Placebo BID (Panel B)
Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.

Experimental: Panel C: MK-8266 TID, 1.8 mg/Placebo
MK-8266 TID, 1.8 mg (0.6 mg every 6 hours [q6hr]), or as matching placebo TID.
Drug: MK-8266 TID, 1.8 mg
MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
Other Name: MK-8266

Drug: Placebo TID (Panel C)
Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.

Experimental: Panel D: MK-8266 TID, 2.4 mg/Placebo
MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.
Drug: MK-8266 TID, 2.4 mg
MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
Other Name: MK-8266

Drug: Placebo TID (Panel D)
Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.

Experimental: Panel E: MK-8266 TID, 2.4 mg/Placebo
MK-8266 TID (Panel E), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel E was initiated after completion of Panel D.
Drug: MK-8266 TID, 2.4 mg
MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
Other Name: MK-8266

Drug: Placebo TID (Panel E)
Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.




Primary Outcome Measures :
  1. Participants Receiving MK-8266 or Placebo Who Experienced At Least One Adverse Event (AE) During Treatment and Postdose Follow-up [ Time Frame: Up to 24 days ]
    Assessment of the number of participants with at least one clinical or laboratory AE in those receiving multiple oral doses of MK-8266. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product.

  2. Participants Receiving MK-8266 or Placebo Who Discontinued Treatment Due to an AE [ Time Frame: Up to 10 days ]
    Assessment of the number of participants receiving MK-8266 who discontinued therapy due to an AE over 10 days of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. The number of participants in any treatment group who discontinued therapy due to an AE was primarily assessed for Days 0-10.

  3. Change From Baseline in Systolic Blood Pressure (SBP) Following Multiple Oral Doses of MK-8266 or Placebo [ Time Frame: Baseline and Day 10 ]
    Assessment of the change from baseline in SBP, obtained using a validated, semi-automated oscillometric device. Evaluated for MK-8266 relative to placebo in participants, as measured by the time weighted average change over 24 hours postdose (TWA^0-24hrs) on dosing Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this analysis.

  4. Heart Rate (HR) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo [ Time Frame: Day 10 (24 hours postdose) ]
    Assessment of HR (beats/min) on Day 10 (24-hours postdose) with MK-8266 relative to placebo in participants, as measured by the time weighted average change over 24 hours postdose (TWA^0-24hrs). Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this analysis. Baseline HR values are shown in the Baseline Characteristics section for Panels A, B, C, D, E.


Secondary Outcome Measures :
  1. Aortic Augmentation Index (AIx) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo [ Time Frame: Day 10 ]
    Assessment of the central, ascending aortic blood pressure augmentation index (AIx), based on measurement of central pulse pressure at selected time points on Day 10, as measured by applanation tonometry of the radial artery. This outcome measure assessed the time weighted average change over 24 hours postdose (TWA^0-24hrs) on dosing Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this assessment.

  2. Change From Baseline in Cyclic Guanosine Monophosphate (cGMP) Following Multiple Oral Doses of MK-8266 or Placebo [ Time Frame: Baseline and Day 10 ]
    Assessment of whole blood samples for cGMP analysis, based on samples obtained predose as well as 4 and 24 hours postdose on Day 1 and Day 10, and predose only on Day 4. The change from baseline in cGMP was assessed at 24 hours postdose on Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this assessment.

  3. Percent Inhibition of Platelet Aggregation Induced by Adenosine Diphosphate (ADP) Following Multiple Oral Doses of MK-8266 or Placebo [ Time Frame: Baseline and Day 10 (5 hours postdose) ]
    The percent inhibition of ADP-induced platelet aggregation from Baseline to 5 hours postdose on Day 10 was assessed and is summarized here. Platelet aggregation was initiated by addition of ADP (2.5 µM) to the participant's blood sample. Aggregation was followed for 5 minutes after addition of the agonist, and the maximum percent of light transmission (extent of aggregation) obtained during this period, as well as the instrument-calculated slope (rate of aggregation), were reported. Post treatment platelet aggregation is expressed as a percent of each participant's pretreatment level of aggregation. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this summary. The data are very limited. On Day 10 only 8 participants received MK-8266 0.8 mg TID and 3 participants received placebo.

  4. Percent Inhibition of Platelet Aggregation Induced by Collagen Following Multiple Oral Doses of MK-8266 or Placebo [ Time Frame: Baseline and Day 10 (5 hours postdose) ]
    The percent inhibition of collagen-induced platelet aggregation from Baseline to 5 hours postdose on Day 10 was assessed and is summarized here. Platelet aggregation was initiated by addition of collagen (2 µg/mL) to the participant's blood sample. Aggregation was followed for 5 minutes after addition of the agonist, and the maximum percent of light transmission (extent of aggregation) obtained during this period, as well as the instrument-calculated slope (rate of aggregation), were reported. Post treatment platelet aggregation is expressed as a percent of each participant's pretreatment level of aggregation. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this summary. The data are very limited. On Day 10, only 8 participants received MK-8266 0.8 mg TID and 3 participants received placebo.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant is male with essential hypertension (high blood pressure)
  • Participant is in good general health (with the exception of hypertension)
  • Participant has a Body Mass Index (BMI) <= 33 kg/m^2 at the Screening visit
  • Participant has a platelet count >= 150,000 cu/mL at the Screening visit
  • Participant has a positive AIx at the Screening visit

Exclusion Criteria:

  • Participant has a history of stroke, chronic seizure, or major neurological disease
  • Participant has a functional disability that can interfere with rising from a seated position to the standing position
  • Participant has any history of a bleeding or clotting disorder
  • Participant has a history of cancer
  • Participant is unable to refrain from or anticipates the use of any prescription or non-prescription medication
  • Participant consumes excessive amounts of alcohol or caffeinated beverages daily

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01096160


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01096160    
Other Study ID Numbers: 8266-002
2010-018654-13 ( EudraCT Number )
First Posted: March 30, 2010    Key Record Dates
Results First Posted: August 12, 2019
Last Update Posted: August 12, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php
Keywords provided by Merck Sharp & Dohme Corp.:
Hypertension
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases